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Abstract
Background: Although horizontal gene transfer plays a pivotal role in bacteriophage evolution, many lytic phage
genomes are clearly shaped by vertical evolution. We investigated the influence of minor genomic deletions and
insertions on various phage-related phenotypic and serological properties.
Findings: We collected ten different isolates of Pseudomonas aeruginosa bacteriophage jKMV. All sequenced
genomes (42-43 kb, long direct terminal repeats) are nearly identical, which intuitively implied strongly similar
infections cycles. However, their latent periods vary between 21 and 28 minutes and they are able to lyse between
5 and 58% of a collection of 107 clinical P. aeruginosa strains. We also noted that phages with identical tail
structures displayed profound differences in host spectra. Moreover, point mutations in tail and spike proteins were
sufficient to evade neutralization by two phage-specific antisera, isolated from rabbits.
Conclusion: Although all analyzed phages are 83-97% identical at the genome level, they display a surprisingly
large variation in various phenotypic properties. The small overlap in host spectrum and their ability to readily
escape immune defences against a nearly identical phage are promising elements for the application of these
phages in phage therapy.
The potential use of lytic bacteriophages as alternative
therapeutic agents against antibiotic-resistant bacteria
has been widely documented [1-3]. This renewed inter-
est in phage therapy resulted in human clinical trials
[ 4 , 5 ]a n dac o n s i d e r a b l er i s eo fc o m m e r c i a li n t e r e s t[ 6 ] .
Potential downsides of phage applications, i.e. their rela-
tively narrow host range and emerging bacterial resis-
tance, are often countered by the proposed use of
mixtures (cocktails) of phages targeting different hosts
and/or host receptors. A popular argument in favour of
these cocktails is the sheer abundance of phages in nat-
ure (10
31 particles worldwide) and the ease of isolating
new phages infecting phage-resistant bacteria [7].
In spite of their ubiquitous character, numerous stu-
dies suggest the existence of only a limited number of
virulent phage ‘types’ targeting a specific bacterial spe-
cies. For example, despite decades of intensive research,
only 17 and 13 distinct phage species infecting the
model organisms Escherichia coli and Pseudomonas aer-
uginosa are known [8,9]. Nearly all newly isolated lytic
phages infecting these organisms cluster within existing
species and carry genomes which are often over 90%
identical at the nucleotide level [10-12]. As this limited
global diversity might hamper the composition of truly
diverse phage cocktails, we were interested in the impact
of these subtle “intraspecies” genomic insertions and
deletions on infection-related and serological properties
of lytic bacteriophages.
As a model species, we choose the virulent P. aerugi-
nosa phage jKMV which resembles the classic coliph-
age T7 in morphology and overall genome architecture
[13]. It was also the first known T7-related phage
encoding a single-subunit RNA polymerase gene down-
stream its DNA metabolism genes instead of in the
early genomic region [13]. Up to now, three phages
infecting P. aeruginosa (LKD16, jKF77 and LUZ19)
have been reported to be 83-90% identical to jKMV at
the nucleotide level [14-16]. In addition, phage LUZ2
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de novo analysis of structural phage proteins [12].
Phages PT2, PT5, PT6, PNC101 and PNM were isolated
from Mtkvari River in Georgia [17] and added to our
existing collection of jKMV-related isolates (Table 1). We
also included the more distantly related Pseudomonas
phage LKA1 in this analysis; LKA1 shares significant
sequence similarity for only 48% of its gene products but
has a conserved functional genome organization and gene
order [14]. With the exception of LKA1 which forms
small plaques (1 mm), all of these phages produce large
(4-10 mm diameter) clear plaques. As members of the
family Podoviridae, these viruses possess icosahedral heads
(diameter of 50-60 nm) and 10-12 nm noncontractile tails.
With the exception of LKA1, all the analyzed phages lyse
P. aeruginosa cells 21 to 28 minutes after infection at 37°C
upon the release of between 116 and 166 newly produced
virions (Table 1).
Infectivity screens on various outer membrane
mutants of P. aeruginosa unambiguously identified the
necessity for Type IV pili for successful infection of all
jKMV-like phages except for LKA1, which depends on
algC expression. The presence/absence of bacterial fla-
gella (encoded by fliC) has no influence on phage infec-
tion (data not shown). Despite this common type IV pili
dependence, subsequent screens on a large collection of
114 clinical P. aeruginosa strains showed profound dif-
ferences in host range. Between 18 (jKMV) and 62
(PT6) P. aeruginosa strains were sensitive to phage
infection, while the more distantly related phage LKA1
can only lyse six strains from our collection (Figure 1A,
Additional file 1). This observation pointed out varia-
tions in secondary adsorption mechanisms and intracel-
lular development, and provoked interest in the genome
sequences of these new jKMV-related isolates.
Using traditional Sanger dideoxy methods for PNM and
454 pyrosequencing for PT2 and PT5, the complete
genome sequences of these phages were determined
(Table 1, Figure 1). All three phages display high
nucleotide similarity (94-97% identity) to jKMV, except
for a 382 bp region located between ORF3 and 4 (Figure
1), which was earlier associated with a localized single-
stranded nick on the non-coding strand in the related
phages LUZ19 and jKF77 [16]. As jKMV is the only
phage of this species which has lost this nick, it is most
p r o b a b l yam o r er e c e n tr e p r e s e n t a t i v eo ft h i sp h a g e
species.
When comparing these newly sequenced genomes to
all known jKMV-related isolates at the protein level, the
extraordinary conservation throughout their genomes is
Table 1 Overview of jKMV-related bacteriophages included in this study, all infecting P. aeruginosa.
Phage Isolated
in
Genome
(bp)
#
ORFs
DTR
length
GC
(%)
jKMV
identity
a
Accession
number
Kadsorption
(ml/min)
b
Latent
period (min)
Burst size
(PFU/cell)
KAPS/
PT5
c
KAPS/
PNC101
c
jKMV Moscow,
Russia
42,519 52 414 62.3 100 NC_005045 1.6 × 10
-8 28 116 259 849
LKD16 Leuven,
Belgium
43,200 54 428 62.6 83 NC_009935 - 27 120 87.5 -
LUZ19 Leuven,
Belgium
43,548 54 472 62.2 89 NC_010326 1.2 × 10
-7 22 122 - -
jKF77 Moscow,
Russia
43,152 53 454 62.8 90 NC_012418 1.5 × 10
-8 23 129 56.2 -
PNM Tbilisi,
Georgia
42,721 51 422 62.3 94 - ND ND ND - 23
PT2 Tbilisi,
Georgia
42,961 54 488 62.0 97 NC_011107 9.2 × 10
-9 21 116 737 51
PT5 Tbilisi,
Georgia
42,954 52 413 62.0 95 NC_011105 7.3 × 10
-9 21 134 598 679
PT6 Tbilisi,
Georgia
ND ND ND ND ND - 2.1 × 10
-8 25 166 257 857
PNC101 Tbilisi,
Georgia
ND ND ND ND ND - ND ND ND 60 753
LUZ2 Leuven,
Belgium
ND ND ND ND ND - ND ND ND 270 -
LKA1 Leuven,
Belgium
41,593 56 298 60.9 ND NC_009936 3.9 × 10
-9 41 225 - -
aIdentity with jKMV, expressed as % identical nucleotides according to the Stretcher algorithm (EMBOSS suite).
bThe adsorption constant k was calculated from the unabsorbed phage at a multiplicity of infection of 1:1 by applying the formula ka = 2.3/Bt log P0/P, where P0
is initial number of phage, P is number of unabsorbed phage particles after time t and B is number of bacteria (4). ND, not determined.
cSerological neutralization assay using PT5 and PNC101 APS. Dilutions (1/50- 1/1000) of APS were mixed with 10
6 bacteriophage, samples were titered after
different incubation times (5, 15 and 30 min) at 37°C. K, rate constant of neutralization, defined as k = 2.3 D/t logP0/P, where P0 - count of bacteriophage
plaques at zero time, P - count of bacteriophage plaques after t time, D - dilution of APS.
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the unrelated ORFs 17.1 in LKD16 and jKF77) and dele-
tions (e.g., ORF2 in jK F 7 7 ,O R F 2 0i nP N M ) ,t h eg e n -
omes have been stably maintained over time and
location. The only phage encoding an additional struc-
tural protein is LUZ19 (gp49), which might cause subtle
differences in virion. The tail fiber regions of jKMV,
PT2 and PNM (and of the partially sequenced phage
PT6) are 99.5-100% identical, strongly suggesting identi-
cal reception/adhesion mechanisms. A similar conserva-
tion of tail genes is also present between LUZ19 and
jKF77 (Figure 2). In contrast, these genes are far less
conserved in PT5 (25-52% amino acid identity to
jKMV), whose tail fibers are more related to phage
LKD16 (61-94% amino acid identity). In contrast to clear
differences in the tail fibers genes of PT5 and PNM, their
early coding region is completely identical (Figure 2).
Intriguingly, the fact that jKMV, PT2, PNM and PT5
have nearly identical virions and/or early regions does
not correlate to their respective host spectra. As shown
in Figure 1B, only six P. aeruginosa strains are lysed by
all four phages and 30 strains can only be targeted by a
single phage.
In a final step, the serological relatedness of these
phages was studied by using a classical cross neutraliza-
tion method [18]. Two anti-phage sera (APS) were
obtained by a two-step immunization of three Swiss
white rabbits with phages PT5 and PNC101. Each rabbit
was injected intramuscularly with a 1:1 (vol/vol) mixture
of phage (10
10 pfu/ml) and adjuvant (Freund’s complete
adjuvant, Difco). One month later, a secondary immuni-
zation was performed by injecting phage (1 ml,
10
11 pfu/ml) without adjuvant. After two weeks, blood
was taken from the left ventricle of the heart. This
blood was allowed to clot, the APS was filtered
(0.45 μmp o r es i z e )a n ds t o r e da t4 ° C .S u b s e q u e n tn e u -
tralization assays with these APS showed significant var-
iation in serological response among the tested phages,
as only jKMV and PT5 were efficiently neutralized by
both antisera (Table 1). Phages LKA1 and LUZ19 were
not neutralized to any significant degree by either APS,
while the inactivation of LKD16, jKF77 and PNM was
at least tenfold less efficient than of the phages used for
the APS production.
When looking into these results in more detail, some
surprising observations were made. One would expect
that neutralizing antibodies primarily function through
interaction with capsid and/or tail (fibers) proteins of
these phages. It is therefore curious that PT2 but not
PNM is neutralized by APSPT5, since the structural
proteins of PT2 and PNM are all >99.5% identical
(Figure 2). Comparing the genomes of these three
phages, the only non-silent structural mutations present
in PT2 and PT5 in comparison to PNM are found in
the tail tubular proteins A (P20-L20,K 55-R55,T 102-P102,
R115-H115)a n dB( D 26-G26, T111-N111, V142-I142,A 298-
G298,G 329-D329,R 363-S363,A 644-V644,P 660-S660,A 784-
V784). These amino acids substitutions are conserved in
jKMV, explaining the sensitivity of this phage for
APSPT5. A similar finding was observed using the anti-
phage serum produced against the non-sequenced phage
PNC101. This serum was over tenfold more effective in
neutralizing jKMV and PT5 than PT2 and PNM,
despite 100% identity of their capsid and connector pro-
teins (Table 1, Figure 2). This time, the difference might
be correlated to four amino acid substitutions in the
spike protein (gp48) of PT2 and PNM.
Discussion
Although horizontal gene transfer plays a pivotal role in
bacteriophage evolution, many lytic phage genomes are
clearly shaped by vertical evolution. The high level of
genomic conservation (83-97% identity) observed within
the ‘phiKMV-like viruses’ is a common theme among
Figure 1 Host range analysis of the jKMV-like viruses. A.H o s t
range analysis of ‘phiKMV-like viruses’ using a collection of 114
clinical P. aeruginosa strains. In this assay, 10
6 pfu were spotted on a
bacterial lawn and checked for lysis. See additional files for more
information on the P. aeruginosa strains and for detailed spectra. B.
Host range comparison of four phages displaying >94% nucleotide
identity throughout their genomes, stating the number of strains
which are uniquely or commonly lysed by PNM, PT2, PT5 and
phiKMV.
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example, the genome of Roseophage SIO1 was found to
be completely conserved in isolates sampled over many
years in various places [11]. Typically, strongly related
phages attach to the same receptor and carry out a
highly comparable infection cycle. At first glace, this is
indeed the case for all analyzed jKMV-like viruses.
They are all pili-dependent and quickly lyse their host
upon the release of up to 166 newly produced particles.
During this study we noticed that small “intraspecies”
genomic variations can have essential phenotypic conse-
quences towards the applications of these phages in
therapeutic settings. First of all, only limited overlaps in
host spectrum exist between isolates with identical tail
fibers and/or early genome regions, implying that minor
genomic changes can cause a significant shift in infectiv-
ity range. Although these differences could be attributed
to the evasion of CRISPR repeats [19], a recent survey
did not find a single spacer matching a lytic bacterioph-
age sequence in 122 clinical P. aeruginosa strains [20].
Alternatively, small point mutations could help in the
evasion of host restriction-modification systems [21]. In
any case, this illustrates the versatility of a phage gen-
ome to evade host defenses.
Moreover, phage therapy seems not be hindered by
the adaptive immune system, since minor variations in
tail/capsid structures seem sufficient to evade antibody
binding. This confirms observations made by Vitiello
and colleagues [22], who reported a long-circulating
mutant of phage l which carried only a single mutation
in the major capsid protein. As phages have a virtually
unlimited potential of subtly modifying their virion, the
potential is present to quickly overcome host immune
responses and bacterial resistance during phage therapy.
Additional material
Additional file 1: Detailed host spectra of the analyzed jKMV-like
viruses. Host range analysis of ‘phiKMV-like viruses’ using a collection of
114 clinical P. aeruginosa strains. In this assay, 10
6 pfu were spotted on a
bacterial lawn and checked for lysis. The file contains information on the
origin of the bacterial strains (country/sampling site) and the level of lysis
caused by addition of the phage.
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